— Know what they know.
Not Investment Advice

HSKA NASDAQ

Heska Corporation
1W: +0.1% 1M: +2.5% 3M: +43.7% 1Y: +27.4% 3Y: +32.0% 5Y: +12.3%
$119.99
Last traded 2023-06-12 — delisted
NASDAQ · Healthcare · Medical - Devices · $1.3B mcap · 10M float · 3.45% daily turnover
Smart Money Score
No convergence signal
Key Statistics
Market Cap$1.3B
52W Range57.83-120.03
Volume330,887
Avg Volume354,981
Beta1.60
Dividend—
Analyst Ratings
8 Buy 8 Hold 0 Sell
Consensus Buy
Company Info
CEOKevin S. Wilson
Employees808
SectorHealthcare
IndustryMedical - Devices
IPO Date1997-07-01
3760 Rocky Mountain Avenue
Loveland, CO 80538
US
970 493 7272
About Heska Corporation

Heska Corporation provides specialized diagnostic and animal health products, predominantly for canine and feline veterinary care markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. Its product line includes a variety of veterinary chemistry analyzers: the Element DC, DCX, and DC5x series, along with the Element RC, RCX, and RC3X systems, all tailored for blood chemistry and electrolyte analysis. For hematological assessments, Heska offers the Element HT5 and scil Vet abc Plus analyzers, capable of measuring blood cell and platelet counts, as well as hemoglobin levels. The company also supplies Element POC analyzers for blood gas and electrolyte testing, Element i immunodiagnostic analyzers, and the Element COAG and Element AIM veterinary analyzers for coagulation studies. Beyond analytical instruments, Heska's offerings extend to advanced imaging and clinical solutions such as HeskaView Telecytology, which provides automated microscopic slide scanning equipment for clinics, and IV infusion pumps. They also distribute digital radiography hardware, including mobile units, sophisticated ultrasound systems, and Cloudbank, a web-based platform for image storage. For rapid, in-clinic detection, point-of-care products are available to identify antigens and antibodies associated with infectious and parasitic diseases in animals. Therapeutic options include Tri-Heart Plus chewable tablets for treating canine heartworm, ascarid, and hookworm infections. The company also specializes in allergy management, offering ALLERCEPT definitive allergen panels for diagnosis and personalized therapy shots or drops. Furthermore, Heska develops a range of vaccines for bovine health. It supplies biological and pharmaceutical products to other animal health companies and offers comprehensive turnkey services encompassing research, licensing, production, labeling, packaging, validation support, and distribution. Products are distributed to veterinarians via a direct telephone sales force, third-party distributors, trade shows, print advertisements, and other strategic partnerships. Founded in 1988, the company was initially known as Paravax, Inc. before rebranding as Heska Corporation in 1995. Its corporate headquarters are located in Loveland, Colorado.

Latest News
No recent news

Recent Insider Trades

NameTypeSharesPriceDate
Davis Stephen L D-Return 500 $120.00 2023-06-13
Hasenmaier Joachim A D-Return 2,004 $120.00 2023-06-13
Eyl Steven M. A-Award 4,056 — 2023-06-13
Eyl Steven M. A-Award 33,111 — 2023-06-13
Eyl Steven M. D-Return 1,146 $18.13 2023-06-13

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms